Claims for Patent: 4,066,755

Summary for Patent: 4,066,755

Title:	Phenylaminoethanol derivatives for treating hypertension
Abstract:	Compounds of the formula: ##STR1## and physiologically acceptable acid addition salts thereof, in which R.sup.1 is A. an arylalkyl group, the alkyl portion of which contains from 1 to 6 carbon atoms and the aryl portion of which may be substituted by one or more alkoxy groups or hydroxy groups; or B. an aryloxyalkyl group, the alkyl portion of which contains from 1 to 6 carbon atoms, and the aryloxy portion of which is substituted with one or more alkoxy or hydroxy groups. These compounds have a blacking action on both .alpha.- and .beta.-adrenergic receptors and are useful in treating hypertension. Processes for the production of these compounds and pharmaceutical compositions containing them are also provided.
Inventor(s):	Lunts; Lawrence Henry Charles (London, EN), Collin; David Trevor (London, EN)
Assignee:	Allen & Hanburys Limited (London, EN)
Application Number:	05/753,558
Patent Claims:	1. A pharmaceutical composition for the treatment of hypertension, comprising as active ingredient, an effective amount of 5-[1-hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl]salicylamide or a physiologically acceptable acid addition salt thereof in association with a non-toxic pharmaceutically acceptable carrier. 2. A composition as claimed in claim 1 in which said active ingredient is 5-[1-hydroxy-2-(1-methyl-3-phenylpropyl) aminoethyl] salicylamide. 3. A composition as claimed in claim 1 in which said active ingredient is 5-[1-hydroxy-2-(1-methyl-3-phenylpropyl) aminoethyl) salicylamide hydrochloride. 4. A composition as claimed in claim 1 in dosage unit form containing from 5 mg to 1000 mg of said active ingredient. 5. A composition as claimed in claim 4 containing from 20 mg to 200 mg of said active ingredient. 6. A composition as claimed in claim 5 in the form of a tablet. 7. A method of treating a human patient suffering from hypertension by blocking both .alpha.- and .beta.-adrenergic receptors in the patient, characterized in that there is administered orally, by suppository or by injection, an effective amount of a compound having both .alpha.- and .beta.-blocking activity, which compound is 5-[1-hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide or a physiologically acceptable acid addition salt thereof. 8. A method as claimed in claim 7 in which said compound is administered orally. 9. A method as claimed in claim 8 in which said compound is administered in tablet form. 10. A method as claimed in claim 9 in which each tablet contains from 20 mg to 200 mg of said compound.